Skip to main content

Advertisement

Open Peer Review Reports for: Randomized phase II study of the PDGFRα antibody olaratumab plus liposomal doxorubicin versus liposomal doxorubicin alone in patients with platinum-refractory or platinum-resistant advanced ovarian cancer

Back to article

Pre-publication versions of this article are available by contacting info@biomedcentral.com.

Original Submission
27 Jun 2018 Submitted Original manuscript
9 Aug 2018 Author responded Author comments - William McGuire
Resubmission - Version 2
9 Aug 2018 Submitted Manuscript version 2
1 Sep 2018 Reviewed Reviewer Report - Claire F. Verschraegen
15 Sep 2018 Reviewed Reviewer Report - Franco M. Muggia
21 Sep 2018 Reviewed Reviewer Report - Robert Naumann
30 Oct 2018 Author responded Author comments - William McGuire
Resubmission - Version 3
30 Oct 2018 Submitted Manuscript version 3
2 Nov 2018 Reviewed Reviewer Report - Claire F. Verschraegen
21 Nov 2018 Reviewed Reviewer Report - Franco M. Muggia
6 Dec 2018 Author responded Author comments - William McGuire
Resubmission - Version 4
6 Dec 2018 Submitted Manuscript version 4
Publishing
9 Dec 2018 Editorially accepted
27 Dec 2018 Article published 10.1186/s12885-018-5198-4

How does Open Peer Review work?

Open peer review is a system where authors know who the reviewers are, and the reviewers know who the authors are. If the manuscript is accepted, the named reviewer reports are published alongside the article. Pre-publication versions of the article are available by contacting info@biomedcentral.com.

You can find further information about the peer review system here.

Advertisement